Cybin has dosed the last patient in Part B of its three-part CYB004-E Phase I clinical trial of CYB004 in healthy volunteers.

CYB004 is being evaluated as a potential therapy for the treatment of generalised anxiety disorder with or without major depressive disorder.

The study is evaluating the pharmacokinetics, pharmacodynamics, and safety of escalating doses of intravenous N,N-dimethyltryptamine (IV DMT) molecule CYB004 in healthy subjects.

Being conducted at the Centre for Human Drug Research in the Netherlands, the CYB004-E study is said to be one of the largest Phase I DMT trials till date.

Cybin CEO Doug Drysdale said: “We are pleased with the continued progress we are making with our CYB004 programme and excited to reach our next key milestone of first-in-human dosing with our novel CYB004 molecule.

“Through Part C of the trial, we will have the ability to evaluate CYB004 in humans earlier than expected and potentially demonstrate the advantages of deuteration on pharmacokinetic/pharmacodynamic parameters, enabling a less invasive and more convenient dose form that may eliminate the need for specialised and costly clinical centres for dosing.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Part C of the study intends to evaluate IV bolus along with infusion regimens of CYB004 in a crossover manner.

For further clinical trials, dose selection and formulation will be decided based on the results of Part B and C studies.

Topline data from the completed Phase I study is expected in the third quarter of this year.